News

February 19, 2020February 19, 2020

Potential CAR T-cell Therapy Targeting ROR1 Seen to Clear Cancer in Leukemia Mouse Model

News

A potential new CAR T-cell therapy by Oncternal Therapeutics showed strong activity against leukemia in mice, completely eliminating cancer cells from major “tissue reservoirs” in four weeks and extending survival by ... Read more

February 17, 2020February 17, 2020

Opdivo Extends Survival in Pretreated Advanced Stomach Cancer Patients, Phase 3 Trial Results Show

News

The immune checkpoint inhibitor Opdivo (nivolumab) may be a safe and effective treatment for people with advanced gastric or esophagogastric junction cancer who failed standard chemotherapy regimens, results from a Phase 3 ... Read more

February 14, 2020February 14, 2020

Ilixadencel Improves Responses, Extends Survival in Newly-diagnosed Metastatic Kidney Cancer, Trial Results Show

News

Adding Immunicum‘s ilixadencel to standard surgical and medical treatment for newly-diagnosed metastatic renal cell carcinoma — the most common form of kidney cancer — increases patient responses, duration of response, and appears ... Read more

February 12, 2020February 12, 2020

Pepinemab-Bavencio Combo Shows Positive Anti-Tumor Activity in Advanced Lung Cancer, Phase 1/2 Trial Shows

News

A combination of Vaccinex‘s investigational antibody pepinemab and the immune checkpoint inhibitor Bavencio (avelumab) was well-tolerated and showed signs of lasting anti-tumor activity in patients with advanced non-small cell lung cancer ... Read more

February 10, 2020February 10, 2020

Geneos to Test GNOS-PV02 Cancer Vaccine in Triple Combo Trial for Advanced Liver Cancer

News

Geneos Therapeutics is gearing up to initiate a Phase 1/2 trial of a triple immunotherapy combination, including its patient-specific cancer vaccine GNOS-PV02, in people with advanced hepatocellular carcinoma (HCC), the ... Read more

February 7, 2020February 7, 2020

Bristol-Myers Squibb Withdraws European Application of Opdivo-Yervoy as Initial Treatment for Advanced NSCLC

News

Bristol-Myers Squibb has withdrawn its application to the European Medicine Agency (EMA) requesting the use of Opdivo (nivolumab) plus Yervoy (ipilimumab) combination therapy as a first-line treatment for people with ... Read more

February 3, 2020February 14, 2020

First Patient Dosed in Proof-of-concept Study of CS1001 Plus Stivarga for Advanced Solid Tumors

News

CStone Pharmaceuticals has dosed the first patient in a clinical trial designed to evaluate CS1001, the company’s experimental PD-L1 inhibitor, in combination with Bayer’s Stivarga (regorafenib), for the treatment of advanced ... Read more

January 27, 2020February 26, 2020

Newly Discovered T-cell Receptor May Lead to More ‘Universal’ Cancer Therapy, Study Suggests

News

A newly discovered receptor in T-cells — immune cells with the ability to kill tumors — makes these cells able to recognize and eliminate several cancer types, without harming healthy ... Read more

January 27, 2020January 31, 2020

Cabometyx, Opdivo, Yervoy Triple Combo Shows Potential Benefits in Advanced HCC, Trial Data Show

News

A combination of Opdivo (nivolumab) and Cabometyx (cabozantinib), with or without Yervoy (ipilimumab), induces clinically meaningful responses in people with advanced hepatocellular carcinoma (HCC) — the most common type of ... Read more

January 27, 2020February 6, 2020

NeoImmuneTech Cleared to Test Hyleukin-7, Keytruda Combo in Trial for Advanced Solid Tumors

News

NeoImmuneTech has been cleared to initiate a Phase 1b/2a trial to determine the optimal dosing and evaluate the anti-tumor activity of its Hyleukin-7 (NT-I7), used in combination with Merck’s Keytruda (pembrolizumab), ... Read more